The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
Abstract Background During the COVID-19 pandemic, some populations, including immunocompromised patients, could not tolerate COVID-19 vaccination or had low responses. Evusheld is a combined neutralizing monoclonal antibody containing tixagevimab and cilgavimab. The World Health Organization (WHO) h...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2024-01-01
|
| Col·lecció: | European Journal of Medical Research |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s40001-023-01549-x |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|